Latest Articles

Chronic Myeloid Leukemia EUTOS Long-Term Survival Score Outperforms Sokal in TKI-Treated CML

EUTOS Long-Term Survival Score Outperforms Sokal in TKI-Treated CML

EUTOS long-term survival score better predicted prognosis for those with chronic myeloid leukemia who had been treated with TKIs—especially among elderly patients.

Multiple Myeloma Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma

Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma

The findings may support the triplet regimen as a new standard of care for these patients, according to Dr Facon.

Renal Cell Carcinoma The Changing Treatment Landscape for Advanced Renal Cell Carcinoma

The Changing Treatment Landscape for Advanced Renal Cell Carcinoma

Interferon or high-dose interleukin-2 were the only available options for the treatment of metastatic RCC until 2005.

Multiple Myeloma Early-Access Daratumumab Trial Supports Safety in Relapsed, Refractory MM

Early-Access Daratumumab Trial Supports Safety in Relapsed, Refractory MM

Researchers also used the trial to collect more information on safety, patient‐reported outcomes, and a specific premedication treatment protocol.

Prostate Cancer Men With Prostate Cancer Willing to Accept Worse Survival Odds to Improve QoL

Men With Prostate Cancer Willing to Accept Worse Survival Odds to Improve QoL

Trade-offs should be carefully considered, as data have indicated that many QoL factors eventually even out.

General Oncology Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

Breast Cancer Liquid Biopsy as a Surveillance Tool for Breast Cancer Follow-Up

Liquid Biopsy as a Surveillance Tool for Breast Cancer Follow-Up

High-risk early breast cancer patients with circulating tumor cells 2 years after chemotherapy had greater risk of recurrence. Possible interventions are needed.

General Oncology Treatment-Related Hyperprogression: Concerns Continue to Mount

Treatment-Related Hyperprogression: Concerns Continue to Mount

Evidence is growing to support the idea that immune checkpoint inhibitors can speed up tumor growth, although the exact mechanism of how this occurs is still unclear.

Breast Cancer Conditional 10-Year Breast Cancer Recurrence Rates Decline Regardless of Subtype

Conditional 10-Year Breast Cancer Recurrence Rates Decline Regardless of Subtype

Among 4 specific breast cancer stages, T2N1 cancers showed the highest risk for local recurrence, regional recurrence, and distant metastases within 10 years from diagnosis.

Lung Cancer Trials, Collaboration Might Help Reduce Survival Disparities Between Community, Academic Cancer Centers

Trials, Collaboration Might Help Reduce Survival Disparities Between Community, Academic Cancer Centers

Better collaboration between community and academic cancer centers could benefit patients.

Lymphoma New Algorithm Improves Outcome Prediction for Diffuse Large B-Cell Lymphoma

New Algorithm Improves Outcome Prediction for Diffuse Large B-Cell Lymphoma

The model was developed using machine learning techniques and programmed with data from a Danish cancer registry.

General Oncology Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

Chronic Myeloid Leukemia 2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML

2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML

The majority of patients studied who stopped TKI therapy remained treatment-free at 3 years.

Skin Cancer Encorafenib Plus Binimetinib Offers a New Option for MEK+BRAF Inhibition

Encorafenib Plus Binimetinib Offers a New Option for MEK+BRAF Inhibition

In the immunotherapy era, the optimal setting and sequencing of BRAF+MEK inhibition remains unresolved.

Brain Cancer Proteomics Study Reveals New Medulloblastoma Subtypes and Potential Novel Treatment Targets

Proteomics Study Reveals New Medulloblastoma Subtypes and Potential Novel Treatment Targets

Genomic and proteomic studies of medulloblastoma samples helped researchers characterize new cancer subtypes and targets.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs